Solentim, a life sciences company, has won a place in this year’s Deloitte’s UK Technology Fast 50 list following a 1,106% revenue growth over the past four years. Solentim specialises in products used by developers of new biotherapeutic medicines, such as monoclonal antibodies for the treatment of cancer. The company claimed 27th place at a gala awards event in London.
The Deloitte UK Technology Fast 50 is one of the UK’s foremost technology award programmes, celebrating innovation and entrepreneurship. Now in its 21st successful year, it is a ranking of the UK’s 50 fastest-growing technology companies, driven by leading intellectual property and based on revenue growth over the past four years.
The announcement recognises the commercial success of Solentim’s VIPS and Cell Metric products, which have increased the speed of development and regulatory assurance of novel biotherapeutic and biosimilar drugs developed in mammalian cells, a process called Cell Line Development.
Receiving the accolade, Aaron Figg, co-founder and director of Solentim, commented: “We’re really proud to have built a company over the last eight years which has become an industry leader, serving customers on a truly global scale. With the advent and adoption by our customers of the latest biological engineering tools like CRISPR and CAR-T, which are already showing astounding results in the treatment of patients, this is a very exciting time and market space for Solentim.
“This award is testament to our highly skilled and committed team, and we could not be more pleased to have our efforts and success recognised by Deloitte, especially as it closely follows us winning two Queens Awards for Enterprise earlier this year.”